Application Cases

• Olink Combined Multi-Organics Uncovers Systemic Immune Mapping in Infants and Children Infected with New Crowns (Cell, IF=64.5)

  Researchers from the University of Tübingen, Germany, in conjunction with a team from Stanford University, Emory University, and Cincinnati Children's Hospital Medical Center, USA, have conducted an in-depth study of the immune system profiles of infants after they are infected with SARS-CoV-2, a number of variants including Omicron, in the weeks to months after birth. The study, which analyzed 92 inflammation-associated proteins in blood and nasal samples from infants and adult subjects using the Olink Target inflammation panel, demonstrated that infants and children have strong and sustained immunity in the first months after infection, with antibody concentrations showing no signs of decay for up to 300 days. Infants and young children demonstrated a strong mucosal immune response after infection. Atypical innate immunity in the blood manifested itself in the absence of pro-inflammatory markers, high IFNα and high chemokines.

  
• Three Nature heavyweights: Olink Explore landmark study opens new era of large-scale population proteomics

  The three heavyweight studies published in Nature all used data generated by the UK Biobank Pharma Proteomics Project (UKB-PPP), in which 13 international biopharmaceutical companies generated new proteomics data by accessing the UK Biobank. Using the Olink Explore platform, the researchers measured approximately 3,000 protein markers in samples from over 54,000 UK Biobank participants. Combining genomic and proteomic analyses on this unprecedented large-scale population-based cohort study yielded a wealth of new information about gene pairs influencing protein expression and phenotypic outcomes. These findings demonstrate the tremendous value of proteomics in elucidating biological mechanisms, discovering actionable new biomarkers, and accelerating drug development efforts.